|  |
| --- |
| **Supplementary table 2.** Median log neutralizing antibody titers (95% CI) against the three polio serotypes in the six study groups given 1 or 2 doses of IPV from the three different manufacturers (PP data-set), with bOPV at weeks 6, 10 and 14 weeks |
| **One dose of IPV at week 14** (mOPV2 at week 18) | **Two doses of IPV at weeks 14 and 36** |
| Week | **SP-1** | **GSK-1** | **BBio-1** | **Combined** | Week | **SP-2** | **GSK-2** | **BBio-2** | **Combined** |
|  | **Serotype 1** |
| **6** | *196***2.8**(2.5–3.5) | *46***3.0**(2.5–3.5) | *46***3.5**(2.8–4.2) | *288***3.0**(2.8–3.5) | **6** | *192***3.2**(2.5–3.5) | *174***3.2** (2.8–3.5) | *169***3.2** (2.8–3.5) | *535***3.2** (2.8–3.5) |
| **14** | *194***> 10.5**(10.5–10.5) | *46***> 10.5** (10.5–10.5) | *46***> 10.5** (10.5–10.5) | *286***> 10.5** (10.5–10.5) | **14** | *192***> 10.5** (10.5–10.5) | *174***> 10.5**(10.5–10.5) | *169***> 10.5** (10.5–10.5) | *535***> 10.5** (10.5–10.5) |
| **18** | *194***> 10.5** (98.6–100) | *46***> 10.5** (94.5–100) | *45***> 10.5** (94.3–100) | *285***> 10.5** (10.5–10.5) | **36** | *192***> 10.5**(10.5–10.5) | *173***> 10.5** (10.5–10.5) | *169***> 10.5**(10.5–10.5) | *534***> 10.5**(10.5–10.5) |
| **19** | *193***> 10.5**(10.5–10.5) | *45***> 10.5** (10.5–10.5) | *45***> 10.5** (10.5–10.5) | *283***> 10.5**(10.5–10.5) | **40** | *192***> 10.5** (10.5–10.5) | *174***> 10.5** (10.5–10.5) | *169***> 10.5**(10.5–10.5) | *535***> 10.5** (10.5–10.5) |
|  | **Serotype 2** |
| **6** | *196***3.3**(2.8–3.5) | *46***3.2**(2.5–4.08) | *46***3.5**(2.8–4.5) | *288***3.5**(3.2–3.5) | **6** | *192***3.2**(2.8–3.5) | *174***3.5**(3.2–3.5) | *169***3.2**(2.8–3.5) | *535***3.2**(3.2–3.5) |
| **14** | *194***< 2.5**(2.5–2.5) | *46***< 2.5** (2.5–2.8) | *46***2.7** (2.5–3.2) | *286***< 2.5** (2.5–2.5) | **14** | *192***< 2.5**(2.5–2.5) | *174***< 2.5**(2.5–2.5) | *169***< 2.5**(2.5–2.5) | *535***< 2.5**(2.5–2.5) |
| **18** | *194***4.8**(4.5–5.2) | *46***5.2**(4.3–6.2) | *45***4.8**(4.2–5.5) | *285***4.8**(4.5–5.2) | **36** | *192***4.0**(3.8–4.5) | *173***4.2**(3.5–4.5) | *169***4.5**(4.2–5.2) | *534***4.2**(3.8–4.5) |
| **19** | *193***7.5**(6.8–8.2) | *45***6.8**(6.2–7.8) | *45***8.5**(7.2–9.2) | *283***7.5**(6.8–7.8) | **40** | *192***> 10.5** (10.5–10.5) | *174***> 10.5** (10.5–10.5) | *169***> 10.5** (10.5–10.5) | *535***> 10.5** (10.5–10.5) |
|  | **Serotype 3** |
| **6** | *196***< 2.5**(2.5–2.5) | *46***< 2.5** (2.5–2.5) | *46***< 2.5**(2.5–2.5) | *288***< 2.5** (2.5–2.5) | **6** | *192***< 2.5** (16.0–25.5) | *174***< 2.5** (20.8–31.7) | *169***< 2.5**(19.3–30.1) | *535***< 2.5** (20.5–26.5) |
| **14** | *194***> 10.5**(10.5–10.5) | *46***> 10.5** (10.5–10.5) | *46***> 10.5** (10.5–10.5) | *286***> 10.5** (10.5–10.5) | **14** | *192***> 10.5**(10.5–10.5) | *174***> 10.5**(10.5–10.5) | *169***> 10.5**(10.5–10.5) | *535***> 10.5**(10.5–10.5) |
| **18** | *194***> 10.5**(10.5–10.5) | *46***> 10.5** (10.5–10.5) | *45***> 10.5**(10.5–10.5) | *285***> 10.5** (10.5–10.5) | **36** | *192***> 10.5**(10.5–10.5) | *173***> 10.5**(10.5–10.5) | *169***> 10.5**(10.5–10.5) | *534***> 10.5**(10.5–10.5) |
| **19** | *193***> 10.5**(10.5–10.5) | *45***> 10.5** (10.5–10.5) | *45***> 10.5** (10.5–10.5) | *283***> 10.5**(10.5–10.5) | **40** | *192***> 10.5**(10.5–10.5) | *174***> 10.5**(10.5–10.5) | *169***> 10.5**(10.5–10.5) | *535***> 10.5**(10.5–10.5) |